Literature DB >> 7046671

Renal function and hemodynamic studies in low- and normal-renin essential hypertension.

J H Bauer, C S Brooks, R N Burch.   

Abstract

Reduced renal blood flow has been suggested to be both a cause and a consequence of essential hypertension. To test these hypotheses, techniques for the clearance of inulin (Cin) and p-aminohippurate (Cpah) were used to assess renal function and hemodynamic measurements in patients with mild and moderate normal-renin and low-renin essential hypertension and in age-matched normotensive subjects. In our study, compared with age-matched control subjects, normal-renin hypertensive subjects younger than 42 years with basal diastolic BPs less than 100 mm Hg had normal glomerular filtration (Cin) and effective renal plasma flow (Cpah), filtration fraction (Cin/Cpah), and renal blood flow (Cpah/1-hematocrit value). The mean arterial pressure (MAP) and renal vascular resistance (MAP/renal blood flow) were increased. In contrast, compared with age-matched control subjects, normal-renin hypertensive subjects older than 42 years with basal diastolic BPs less than 100 mm Hg and greater than 100 mm Hg had a decreased Cpah and an increased filtration fraction. The MAP was increased, the renal blood flow decreased, and the renal vascular resistance notably increased. Subjects with low-renin essential hypertension had renal function and hemodynamic patterns indistinguishable from those of age matched normal-renin hypertensive subjects with similar basal diastolic BPs. These data suggest that in early normal-renin essential hypertension, the increase in systemic BP is not caused by renal circulatory disturbances. Increased renal vascular resistance, however, may lead to subsequent vascular functional or structural changes, ultimately decreasing effective renal plasma flow but at a rate disproportionate to the glomerular filtration rate.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7046671

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  8 in total

1.  Renal and hormonal effects of alpha 1-adrenoceptor blockade by bunazosin in essential hypertension.

Authors:  Y Hirata; K Fukui; Y Dan; H Matsuoka; T Sugimoto; M Ishii
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

2.  Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes.

Authors:  Felix Stader; Marco Siccardi; Manuel Battegay; Hannah Kinvig; Melissa A Penny; Catia Marzolini
Journal:  Clin Pharmacokinet       Date:  2019-04       Impact factor: 6.447

3.  Acute changes in renal function induced by bisoprolol, a new cardioselective beta-blocking agent.

Authors:  Z Glück; F C Reubi
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 4.  Acute and chronic effects of angiotensin converting enzyme inhibitors on the essential hypertensive kidney.

Authors:  G P Reams; J H Bauer
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

Review 5.  Do calcium channel blockers have renal protective effects?

Authors:  G P Reams
Journal:  Drugs Aging       Date:  1994-10       Impact factor: 3.923

6.  Renal protective effect of long term antihypertensive therapy with enalapril.

Authors:  J H Bauer; G P Reams
Journal:  Drugs       Date:  1988       Impact factor: 9.546

7.  Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.

Authors:  Jan-Frederik Schlender; Michaela Meyer; Kirstin Thelen; Markus Krauss; Stefan Willmann; Thomas Eissing; Ulrich Jaehde
Journal:  Clin Pharmacokinet       Date:  2016-12       Impact factor: 6.447

8.  Repository Describing the Anatomical, Physiological, and Biological Changes in an Obese Population to Inform Physiologically Based Pharmacokinetic Models.

Authors:  Mattia Berton; Sara Bettonte; Felix Stader; Manuel Battegay; Catia Marzolini
Journal:  Clin Pharmacokinet       Date:  2022-06-14       Impact factor: 5.577

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.